Point Biomedical
7
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
42.9%
3 terminated/withdrawn out of 7 trials
57.1%
-29.4% vs industry average
43%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
Role: lead
Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent
Role: lead
Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems
Role: lead
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease
Role: lead
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease
Role: lead
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007
Role: lead
Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease
Role: lead
All 7 trials loaded